PT  - JOURNAL ARTICLE
AU  - MOTOAKI YASUKAWA
AU  - TAKESHI KAWAGUCHI
AU  - NORIKAZU KAWAI
AU  - TAKASHI TOJO
AU  - SHIGEKI TANIGUCHI
TI  - Surgical Treatment for Pulmonary Metastasis of Pancreatic Ductal Adenocarcinoma: Study of 12 Cases
DP  - 2017 Oct 01
TA  - Anticancer Research
PG  - 5573--5576
VI  - 37
IP  - 10
4099  - http://ar.iiarjournals.org/content/37/10/5573.short
4100  - http://ar.iiarjournals.org/content/37/10/5573.full
SO  - Anticancer Res2017 Oct 01; 37
AB  - Background/Aim: Few studies have reported results with pulmonary metastasectomy for pancreatic ductal adenocarcinoma (PDAC), probably because of their extremely poor outcomes. The aim of this study was to review our institutional experience and analyze the outcomes of pulmonary metastasectomy for PDAC. Patients and Methods: A retrospective case-control study of patients undergoing pulmonary metastasectomy for isolated lung metastasis of PDAC between 2004 and 2016. Clinicopathological features were analyzed and survival curves were plotted using the Kaplan–Meier method. Results: Twelve patients were included. The median follow-up period after metastasectomy was 33 months. At the time of analysis, five patients had deceased, two were alive with disease, and five were alive without disease. The median survival time after pulmonary metastasectomy was 47 months. The estimated 3- and 5-year overall survival rates were 62.3% (95%CI=27.8-84.0) and 31.2% (95%CI=1.7-71.7). Conclusion: Outcomes were favorable following pulmonary metastasectomy in selected patients with PDAC.